CD274 and neoplasm: Because variables such tumor infiltrating lymphocytes (TILs), immune checkpoint molecule expression (e.g., PD-L1), and mutation burden can vary within the same subtype, this heterogeneity makes it more difficult to define consistent criteria for patient selection.